BusinesseFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal ChemistryBy Nasdaq OMXApr 26, 2018, 11:31 AM UTC
BusinessAdaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018By Nasdaq OMXApr 25, 2018, 12:02 PM UTC
BusinessAxiom Real-Time Metrics Exhibiting Fusion eClinical Suite at Clinical Operations in Oncology Trials WestBy Nasdaq OMXApr 23, 2018, 11:12 PM UTC
BusinessSpotlight Innovation Subsidiary Celtic Biotech Iowa Announces Results from Two Cohorts of Phase I Trial of Crotoxin for the Treatment of CancerBy Nasdaq OMXApr 18, 2018, 12:48 PM UTC
BusinesseFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual MeetingBy Nasdaq OMXApr 16, 2018, 12:01 PM UTC
BusinessCommunity Oncology Alliance Practice Impact Report Details Consolidation, Shift of U.S. Cancer Care System Into More Expensive Hospital SettingBy Nasdaq OMXApr 12, 2018, 9:30 PM UTC
BusinessCancer Care Teams and Advocates Gather in Washington for Largest Community Oncology Conference EverBy Nasdaq OMXApr 12, 2018, 2:46 PM UTC
BusinessINmune Bio Co-Founder and Chief Scientific Officer Mark Lowdell, PhD, Delivers Keynote at CTERP International ConferenceBy Nasdaq OMXApr 12, 2018, 2:05 PM UTC
